A standardized botanical formulation known as Feibi Recipe No. 2 significantly attenuated pulmonary fibrosis in a progressive mouse model, exerting protective effects across distinct disease stages through the coordinated regulation of iron homeostasis, cellular ferroptosis, and receptor-mediated signaling pathways. The preclinical study, conducted by researchers at the Beijing University of Chinese Medicine and published in Frontiers in Pharmacology, evaluated the therapeutic efficacy and underlying molecular mechanisms of the traditional multi-herb decoction in male C57BL/6J mice subjected to bleomycin-induced lung injury. Across a structured series of time-course histological, biochemical, flow-cytometric, and proteomic evaluations, oral administration of the formula preserved alveolar epithelial cell integrity, suppressed systemic inflammatory signaling, inhibited myofibroblast activation, and markedly reduced late-stage pulmonary collagen deposition, demonstrating a multifaceted protective profile that mirrored and in some respects surpassed the standard iron-chelating comparator agent deferoxamine.
Pulmonary fibrosis, particularly idiopathic pulmonary fibrosis, represents a fatal and progressive interstitial lung disease characterized by the irreversible destruction of alveolar architecture, excessive accumulation of extracellular matrix proteins, and progressive respiratory failure, carrying a dismal median survival of only two to five years following clinical diagnosis. Currently approved pharmaceutical interventions, such as pirfenidone and nintedanib, demonstrate limited clinical utility, slowing disease progression without halting or reversing established fibrotic remodeling while presenting substantial tolerability challenges for many patients. In recent years, abnormal iron metabolism and ferroptosis—a specialized form of regulated non-apoptotic cell death driven by iron-dependent lipid peroxidation and antioxidant system collapse—have emerged as critical drivers bridging initial epithelial damage, chronic inflammation, and aberrant tissue remodeling in fibrotic lung pathology.
Rooted in the clinical lineage of the traditional formulas Qiyin Sanliangsan and Feibi Decoction developed by Professor Ping’an Zhou for refractory respiratory disorders, Feibi Recipe No. 2 was prepared using a refined composition of six botanical drugs: 30 grams of Astragalus mongholicus root, 30 grams of Rhodiola crenulata rhizome and root, 30 grams of Lonicera japonica flower, 20 grams of Scutellaria baicalensis root, 20 grams of Salvia miltiorrhiza rhizome and root, and 10 grams of Glycyrrhiza uralensis rhizome and root. Quality-controlled raw botanical ingredients were subjected to two standardized aqueous extraction cycles at a 1:7.14 drug-to-solvent ratio, yielding a concentrated decoction with a crude botanical-drug equivalent concentration of 2.8 grams per milliliter, a dry-extract yield of 24.4 percent, and a native drug-to-extract ratio of 4.09:1. Subsequent chemical characterization by ultra-high-performance liquid chromatography coupled with tandem mass spectrometry identified diverse putatively annotated bioactive metabolites across positive and negative electrospray ionization modes, prominently including baicalin, wogonoside, baicalein, chlorogenic acid, salidroside, quercitrin, and cryptotanshinone.
To rigorously investigate therapeutic efficacy and stage-specific dynamics, the researchers established an in vivo experimental framework involving 230 adult male C57BL/6J mice across two sequential experimental stages following ethical approval by the Animal Ethics Committee of Beijing University of Chinese Medicine. In Stage I, 180 mice were allocated among six experimental cohorts: an uninjured vehicle control, a bleomycin-injured model group receiving a single intratracheal instillation of 2.5 milligrams per kilogram of bleomycin hydrochloride, three treatment groups receiving daily oral gavage of low, medium, or high doses of Feibi Recipe No. 2 equivalent to 10.51, 21.02, or 42.04 grams per kilogram per day of raw botanical drug, and a positive comparator group receiving daily intraperitoneal injections of 30 milligrams per kilogram of the iron chelator deferoxamine. Daily interventions began twenty-four hours after bleomycin instillation, and prespecified subsets of ten animals per group underwent terminal sampling at days 7, 14, and 21 to capture the full trajectory of acute alveolar damage, evolving interstitial inflammation, and established fibrotic remodeling.
Quantitative morphometric and histopathological assessments revealed that Feibi Recipe No. 2 exhibited a pronounced, non-monotonic dose-response profile, with the medium dose of 21.02 grams per kilogram per day—designated as FBR2-M and corresponding mathematically to the standard human adult clinical dose via body-surface-area conversion—demonstrating superior therapeutic efficacy compared to both lower and higher dose regimens. At the terminal day-21 fibrotic endpoint, blinded morphometric image analyses showed that FBR2-M reduced Masson’s trichrome-positive collagen area, lowered the semiquantitative modified Ashcroft fibrosis score on a zero-to-eight scale, and decreased immunohistochemical collagen I-positive deposition relative to the untreated bleomycin cohort, with all three pairwise comparisons achieving high statistical significance at P < 0.0001. Direct statistical comparisons between the botanical dosing groups confirmed that FBR2-M achieved significantly lower Masson’s positive areas and Ashcroft scores than both FBR2-L and FBR2-H (all P < 0.0001), alongside significantly reduced collagen I expression (P = 0.007 versus FBR2-L; P = 0.002 versus FBR2-H), establishing that doubling the administered botanical dose yielded no additional therapeutic benefit.
Evaluation of time-resolved pathological markers demonstrated that the medium dose of Feibi Recipe No. 2 intervened across multiple distinct cellular processes throughout disease progression rather than merely blunting late-stage architectural distortion. Immunofluorescence tracking of surfactant protein C-positive alveolar type II epithelial cells showed an abrupt, severe loss of epithelial integrity in bleomycin-exposed lungs by day 7; administration of Feibi Recipe No. 2 markedly preserved surfactant protein C expression as early as day 7 (P < 0.0001) and maintained epithelial integrity across days 14 and 21. Simultaneously, enzyme-linked immunosorbent assays demonstrated that the formula significantly suppressed the acute systemic surge of serum interleukin-6 that peaked at day 7 in injured animals (P < 0.0001). During the subsequent fibrotic phase, quantitative immunohistochemical staining revealed that the progressive accumulation of alpha-smooth muscle actin, a hallmark biomarker of myofibroblast differentiation and contractile tissue remodeling, was significantly suppressed by the formula at both day 14 and day 21 (all P <= 0.001), corroborating a coordinated, stage-specific protective sequence.
To explore the broader molecular alterations associated with botanical treatment, the investigators performed high-resolution data-independent acquisition proteomics on lung tissue collected at day 21 from control, bleomycin, and FBR2-M cohorts, followed by parallel reaction monitoring validation. Principal component analysis confirmed clear spatial segregation among the experimental cohorts, identifying 1,429 upregulated and 1,430 downregulated proteins following bleomycin exposure, as well as 231 upregulated and 234 downregulated proteins following herbal intervention. Bioinformatic filtering isolated 256 differentially expressed proteins whose aberrant expression was reversed by Feibi Recipe No. 2. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses revealed that these reversed proteins were heavily concentrated in iron-binding processes, cellular responses to iron ions, heme binding, and the HFE-transferrin receptor complex, as well as canonical ferroptosis, glutathione metabolism, porphyrin metabolism, and mineral absorption pathways, implicating key regulators such as transferrin, transferrin receptor 1, ferritin heavy chain 1, heme oxygenase 1, and glutathione peroxidase 7.
Direct assessments of pulmonary iron handling in Stage I tissue samples substantiated these proteomic predictions, showing that Feibi Recipe No. 2 effectively corrected pulmonary iron overload and reversed aberrant expression of the central iron regulatory protein and iron-responsive element post-transcriptional network. Flow cytometric analysis using the divalent iron-specific fluorescent probe RhoNox-1 revealed marked intracellular accumulation of redox-active ferrous iron in dissociated lung cell suspensions from bleomycin-treated mice that persisted through day 21. Feibi Recipe No. 2 significantly lowered intracellular ferrous iron accumulation across all time points, retaining statistically significant reduction at day 21 (P = 0.040 versus bleomycin) where the standard chelator deferoxamine failed to reach significance (P = 0.062). Perls’ Prussian blue staining at day 7 further confirmed substantial interstitial ferric iron deposition that was markedly blunted by the formula. At the molecular level, bleomycin induced significant elevations in iron regulatory protein 1 protein and Aco1 transcript levels alongside increased transferrin receptor 1 expression, while repressing the sole mammalian iron exporter ferroportin at the protein level without altering its Slc40a1 transcript; Feibi Recipe No. 2 significantly counteracted each of these aberrant shifts.
Parallel evaluations confirmed that the formula sustained cellular antioxidant defenses and mitigated lipid peroxidation and mitochondrial deterioration indicative of ferroptotic damage. Bleomycin exposure triggered profound depletion of reduced glutathione content alongside early downregulation of the master phospholipid hydroperoxidase glutathione peroxidase 4 from day 7 through day 21; treatment with Feibi Recipe No. 2 significantly restored glutathione pools from day 14 onward and prevented glutathione peroxidase 4 protein degradation across all observation periods. In parallel, the herbal decoction significantly attenuated accumulations of the cytotoxic lipid peroxidation end products 4-hydroxynonenal across all time points and malondialdehyde at day 14 (P = 0.025 versus bleomycin), again outperforming deferoxamine (P = 0.070). Furthermore, the intervention suppressed aberrant overexpression of dynamin-related protein 1, a key regulator of mitochondrial fission, and counteracted the progressive collapse of mitochondrial membrane potential assessed by the JC-1 aggregate-to-monomer fluorescence emission ratio, demonstrating comprehensive preservation of mitochondrial homeostasis.
To investigate whether upstream receptor-mediated signaling drives these interconnected iron-regulatory and ferroptotic responses, Stage II examined a separate cohort of 50 mice allocated among five groups: control, bleomycin, FBR2-M, the selective N-methyl-D-aspartate receptor antagonist memantine administered at 10 milligrams per kilogram per day, and a combined cohort receiving FBR2-M alongside the receptor agonist N-methyl-D-aspartate at 8 milligrams per kilogram per day. Pharmacological inhibition of NMDAR with memantine produced therapeutic benefits that closely mirrored Feibi Recipe No. 2, reducing the essential NMDAR subunit GluN1, diminishing iron regulatory protein 1 and transferrin receptor 1 levels, restoring ferroportin expression, decreasing ferrous iron accumulation (P = 0.007 versus bleomycin), reducing lipid peroxidation, and improving Ashcroft scores. In stark contrast, co-administration of the agonist NMDA substantially counteracted the protective actions of Feibi Recipe No. 2, resulting in exacerbated ferrous iron accumulation (P = 0.001 versus FBR2 alone), higher malondialdehyde levels, diminished glutathione reserves, severe loss of mitochondrial membrane potential, and significantly higher Masson’s trichrome collagen deposition and modified Ashcroft scores (both P < 0.0001).
While these integrated in vivo and molecular observations provide compelling evidence linking the antifibrotic efficacy of Feibi Recipe No. 2 to NMDAR signaling modulation, iron-regulatory homeostasis, and ferroptotic suppression, the authors emphasized critical methodological limitations that warrant careful interpretation.
Subject of Research: Preclinical investigation of Feibi Recipe No. 2 mechanisms in bleomycin-induced mouse pulmonary fibrosis
Article Title: Feibi recipe no. 2 attenuates bleomycin-induced pulmonary fibrosis in mice: involvement of N-methyl-D-aspartate receptor-related iron dyshomeostasis and ferroptosis
Article References: Li, Y., Jiao, Y., Cai, Y., Wei, W., Cao, F., Wu, Z., Niu, J., & Liu, T. (2026). Feibi recipe no. 2 attenuates bleomycin-induced pulmonary fibrosis in mice: involvement of N-methyl-D-aspartate receptor-related iron dyshomeostasis and ferroptosis. Frontiers in Pharmacology, 17, Article 1927029. https://doi.org/10.3389/fphar.2026.1927029
Image Credits: AI Generated
DOI: 10.3389/fphar.2026.1927029
Keywords: pulmonary fibrosis, Feibi Recipe No. 2, ferroptosis, bleomycin mouse model, N-methyl-D-aspartate receptor, iron regulatory protein 1, transferrin receptor 1, ferroportin, lipid peroxidation, glutathione peroxidase 4, memantine, Masson’s trichrome, modified Ashcroft score, collagen deposition, alveolar epithelial cells, surfactant protein C, interleukin-6

